Who is sponsoring NCT05446961?

NCT05446961 is sponsored by SENAI CIMATEC.

What drugs are being tested in NCT05446961?

Interventions in NCT05446961: LCLT : 68% elemental L-carnitine and 32 % Tartric acid, Placebo.

What condition does NCT05446961 study?

NCT05446961 studies COVID-19 Virus Infection.

Is NCT05446961 still recruiting?

NCT05446961 is currently completed. Last updated 7 July 2022.

Last reviewed 2022-07-07 · How we verify

NCT05446961

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus

Completed Phase 2 Last updated 7 July 2022

What this trial tests

Phase 2 trial testing LCLT : 68% elemental L-carnitine and 32 % Tartric acid in COVID-19 Virus Infection in 224 participants. Completed in 3 February 2022.

Timeline

1 March 2021

Primary endpoint
1 September 2021

3 February 2022

Quick facts

Lead sponsor	SENAI CIMATEC
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	quadruple
Primary purpose	treatment
Enrollment	224
Start date	1 March 2021
Primary completion	1 September 2021
Estimated completion	3 February 2022
Sites	1 location across Brazil

Drugs / interventions tested

LCLT : 68% elemental L-carnitine and 32 % Tartric acid
Placebo

Conditions studied

COVID-19 Virus Infection — all drugs for COVID-19 Virus Infection →

Sponsor

SENAI CIMATEC — full company profile →

Who can join

Adults 18 to 85, any sex, with COVID-19 Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to assess safety and efficacy of Carnipure tartrate (L-Carnitine and L-tartaric acid - LCLT) supplementation for SARS-Cov-2 infection

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A randomized clinical trial to evaluate the efficacy of L-carnitine L-tartrate to modulate the effects of SARS-CoV-2 infection.
Badaro R, Barbosa JDV, de Araujo Neto CA, Machado BAS, et al · · 2023 · cited 1× · PMID 37545576 · DOI 10.3389/fnut.2023.1134162

Verify or expand the search:

Other SENAI CIMATEC trials

Trials by the same sponsor.

NCT05671796 — Autologous Bone Marrow Stem Cell Transplantation in Patients With Subacute Spinal Cord Injury · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05446961 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SENAI CIMATEC
Last refreshed: 7 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05446961.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing